Chimeric Therapeutics Ltd
ASX:CHM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Companhia de Saneamento do Parana Sanepar
BOVESPA:SAPR4
|
BR |
|
Inzone Group Co Ltd
SSE:600858
|
CN |
Chimeric Therapeutics Ltd
Operating Expenses
Chimeric Therapeutics Ltd
Operating Expenses Peer Comparison
Chimeric Therapeutics Ltd
Glance View
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.
See Also
What is Chimeric Therapeutics Ltd's Operating Expenses?
Operating Expenses
-13.1m
AUD
Based on the financial report for Jun 30, 2025, Chimeric Therapeutics Ltd's Operating Expenses amounts to -13.1m AUD.
What is Chimeric Therapeutics Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-190%
Over the last year, the Operating Expenses growth was -16%. The average annual Operating Expenses growth rates for Chimeric Therapeutics Ltd have been 5% over the past three years , -190% over the past five years .
